IRAK1 and myelodysplastic syndrome: This strategy has demonstrated preclinical efficacy in tumours harbouring MYD88 mutations, and preclinical studies of IRAK1/4 small-molecule inhibitors have reported encouraging preliminary results in melanoma [119], myelodysplastic syndrome (MDS) [120] and T-cell acute lymphoblastic leukaemia (T-ALL) [121,122].